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Abstract
Background: Novel strategies are needed for the elicitation of broadly neutralizing antibodies to the HIV envelope
glycoprotein, gp120. Experimental evidence suggests that combinations of antibodies that are broadly neutralizing in vitro
may protect against challenge with HIV in nonhuman primates, and a small number of these antibodies have been selected
by repertoire sampling of B cells and by the fractionation of antiserum from some patients with prolonged disease. Yet no
additional strategies for identifying conserved epitopes, eliciting antibodies to these epitopes, and determining whether
these epitopes are accessible to antibodies have been successful to date. The defining of additional conserved, accessible
epitopes against which one can elicit antibodies will increase the probability that some may be the targets of broadly
neutralizing antibodies.
Methodology/Principal Findings: We postulate that additional cryptic epitopes of gp120 are present, against which
neutralizing antibodies might be elicited even though these antibodies are not elicited by gp120, and that many of these
epitopes may be accessible to antibodies should they be formed. We demonstrate a strategy for eliciting antibodies in mice
against selected cryptic, conformationally dependent conserved epitopes of gp120 by immunizing with multiple identical
copies of covalently linked peptides (MCPs). This has been achieved with MCPs representing 3 different domains of gp120.
We show that some cryptic epitopes on gp120 are accessible to the elicited antibodies, and some epitopes in the CD4
binding region are not accessible. The antibodies bind to gp120 with relatively high affinity, and bind to oligomeric gp120
on the surface of infected cells.
Conclusions/Significance: Immunization with MCPs comprised of selected peptides of HIV gp120 is able to elicit antibodies
against conserved, conformationally dependent epitopes of gp120 that are not immunogenic when presented as gp120.
Some of these cryptic epitopes are accessible to the elicited antibodies.
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Introduction
The search for a vaccine to prevent the acquisition of HIV
infection is complicated in part by the lack of a convincing
immunological correlate of protection against HIV. Ideally one
would like to elicit both HIV-specific broadly neutralizing
antibodies (Abs) and T cell-mediated immunity, although optimal
immunization strategies for these two types of immune responses
may differ. To date, immunization strategies inducing cytotoxic
CD8 T cells (CTLs) have impressively mitigated the severity of
infection in nonhuman primates following challenge with SIV or
SIV with an HIV envelope (SHIV), but have not prevented the
acquisition of infection.
During the course of natural HIV infection sequential Abs
develop that transiently neutralize existing viral variants, only to
select resistant escape variants, indicating that Abs can inhibit HIV
replication in vivo [1,2,3,4]. However most Abs induced early in the
course of infection are directed primarily against epitopes on the
envelope glycoprotein, gp120, that are not conserved, and are
expressed only on limited isolates within the quasispecies infecting
the patient, allowing for selection of escape mutants [1,2,3,4,5,6]. A
small number of monoclonal antibodies (MAbs) that are able to
broadly neutralize multiple subtype B isolates and some other group
M isolates have been isolated by sampling the B cell repertoire of
HIV infected patients [7,8,9,10,11,12,13,14,15,16,17]. The identi-
fication of these MAbs, directed against epitopes in the CD4-
binding region, a mannose epitope on the glycosylated surface of
gp120, and the membrane-proximal region of gp41 [18] demon-
strates that some patients have B cell clones capable of making
broadly neutralizing Abs. These MAbs have provided insights into
the structure and function of gp120 [19,20,21,22,23].
As a proof of principal, the passive intravenous administration
of a mixture of these human broadly neutralizing MAbs to Rhesus
macaques prior to intravenous or intravaginal challenge with
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exposure can prevent infection [24,25,26,27,28,29,30].
MorerecentlyantiserafromanumberofHIV-infectedindividuals,
usually obtained late in the course of infection, have been described
that are broadly neutralizing [31,32,33] and current studies are
finding that the neutralizing Abs in these sera are directed against a
variety of epitopes on gp120, including some in the CD4 binding
region and in the co-receptor binding regions [31,32,33]. The recent
cloning of single cell immunoglobulin cDNAs from 500 gp140 -
binding memory B lymphocytes from HIV-infected patients with low
viral loads, detected several neutralizing Abs from individual patients
binding to multiple epitopes [16]. These observations are consistent
with the existence of a variety of potential neutralizing epitopes on
gp120. Evidence for the presence of multiple neutralizing epitopes
recognized by Abs in infected individuals is reviewed elsewhere [5]. It
should be appreciated that these human Abs have been induced by
infection, and Abs elicited by immunization may be directed against
different epitopes.
Although broadly neutralizing Abs can be formed in humans,
and under specific experimental conditions are able to prevent
infection in nonhuman primates, successful strategies for eliciting
these or similar Abs by immunization have not yet been identified.
Immunization of experimental animals or humans with recombi-
nant, monomeric gp120 elicits antisera that are neither broadly
neutralizing nor protective [34,35,36], although occasional neutral-
izing MAbs have been detected in these animal antisera [37].
Determinants of the CD4 and chemokine receptor binding sites,
and those that permit the conformational changes required for
viral entry should be conserved. The large conformational changes
occurring upon CD4 binding [38] and the probable lack of a fixed
conformation of unbound gp120 illustrate challenges presented by
this target [39]. Immunization with stabilized trimeric gp120, with
gp120 conformationally altered by sCD4 to expose buried
epitopes, by decreased glycosylation, or with gp120 that has been
engineered to display conserved epitopes often have been
immunogenic, but with few exceptions all have failed to elicit
Abs that are broadly neutralizing [40,41,42,43,44]. Molecular
mimics of epitopes recognized by the existing neutralizing MAbs
against gp120 have been selected by these MAbs, but most have
failed to elicit similar Abs [45,46], although screening of random
peptide phage-displayed libraries, including conformational epi-
topes, with antiserum from a Rhesus monkey infected with a Clade
C SHIV identified epitopes that induced neutralizing antibodies in
mice primed with DNA encoding SHIV env [47]. Recently MAbs
were isolated from a clade A infected individual that recognize
broadly neutralizing conformational epitopes on gp120 only when
in the trimeric form [17]. Conformationally dependent epitopes
should generally be more highly conserved than those defined by a
linear sequence of contiguous amino acid residues, and several
conserved conformational epitopes have been documented,
including some in the V3 loop, against which Abs are neutralizing
[10,48]. To be broadly neutralizing, an Ab should bind to a
conserved epitope with a relatively high affinity. MAbs directed
against an artificial FLAG epitope inserted into a part of the V4
loop of gp120, neutralized viruses, and the ease of neutralization
by the anti-FLAG MAb was a function of the affinity of the MAb
to mutants of the inserted FLAG [49]. Subsequent experiments
indicate that the site of insertion of the tag may significantly
influence the infectivity of the virus, and indicate the exact
positioning of the tag may influence the ability of Abs to neutralize
via this tag [50]. It has been suggested that conserved,
conformationally dependent epitopes of gp120 are poorly
immunogenic and/or inaccessible to Abs [51,52]. We postulate
that determinants exist on gp120 that are cryptic, in that they are
not immunogenic when presented in the form of the whole
glycoprotein, even though they are accessible to Abs should they
be elicited. Some of these may be targets of known broadly
neutralizing Abs, others may be targets of Abs not yet identified.
Strategiesare neededforidentifying additional cryptic, conserved
epitopes, for eliciting antibodies to these epitopes, and determining
whether these epitopes are accessible to antibodies. We have
demonstrated that murine antisera recognizing cryptic, conserved
conformationally dependent epitopes of HIV gp120 can be elicited
by immunization with single sequence, multiple copy peptides
(MCPs), also called MAPS, consisting of 8 identical peptide chains
coupled intoa branched structure viaa core using the a and e ´ amino
groups of lysine [53,54]. These constructs have a molecular weight
of up to 20,000 D, and enable one to immunize against a specific
peptide without eliciting antibodies to large numbers of non-
conserved sequences as occurs after immunizing with gp120, and
without coupling it to a carrier protein, which might dominate the
immunogenicity of the peptide, alter the immunogenicity of the
peptide [55] or elicit lower Ab titers than achieved with the MCP
[54].Weobservedthat theresultingwholeantiseraderived from the
immunized animals bind to native but not fully denatured gp120,
indicating that these immunogens focus an immune response on
conformationally dependent epitopes in gp120 rather than
contiguous linear epitopes [53]. The use of MCPs of a selected
sequence can elicit antisera against conformationally dependent
cryptic epitopes of gp120 formed by that sequence that cannot be
elicited by immunization with the intact glycoprotein. Immuniza-
tion with the homologous monomeric peptide does not elicit Abs
against the epitopes on gp120 recognized by the anti-MCP sera
eventhough high titers of Abs to the monomeric peptide are formed
[53]. This represents a strategy for eliciting Abs to conserved
conformationally dependent epitopes of gp120, against which Abs
are not induced by immunization with gp120 itself.
We now present data on the functional properties of antisera
and MAbs elicited in mice by three MCPs composed of two
related amino acid sequences near the CD4-binding region and
bridging sheet of gp120, encompassing residues 419–439, and
426–441, and a third conserved structure with a less conserved
sequence, residues 363–384, that forms part of the CD4 binding
pocket. The whole antisera as well as MAbs bind to native but not
to completely denatured gp120, indicating that the majority of Abs
in sera elicited by MCPs recognize secondary structures of the
glycoprotein that are also expressed and accessible or partially
accessible on native gp120. The Abs bind to gp120 on the surface
of infected CD4 cells, and recognize cryptic epitopes not
recognized by antisera elicited by gp120, or present at detectable
levels in pooled human anti-HIV serum immunoglobulin
(HIVIG). MAbs elicited by these MCPs bind to gp120 at half
saturation concentrations of 2 nM or less, and one MAb has
moderate neutralizing activity against an easily neutralizable clade
B isolate SF162 [56,57]. This strategy enables one to identify new
potential epitopes in selected domains of gp120, elicit Abs against
these epitopes, and use these Abs to assess whether the epitopes are
accessible in monomeric and oligomeric gp120.
Results
Immunogenicity of MCPs
Because of their larger molecular weight and constrained
secondary structure, immunization of mice with MCPs representing
epitopes of gp120, elicits high titered antisera recognizing native
recombinant gp120, whereas immunization with the homologous
m o n o m e r i cp e p t i d e sd o e sn o t ,e v e nt h o u g hi ns o m es t r a i n so fm i c e
high titers of Abs to the monomer peptide are formed (Table 1 and
Immunogens to Gp120 Epitopes
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titers with MCPsofthesamesequence (not shown), butMCPs display
additional secondary structures or epitopes not present on the
homologous monomer [53]. The 419–439 and 426–441 sequences
are in the b20–b21 hairpin domain, which changes conformation
within the gp120 molecule upon CD4 binding, and is part of the
bridging sheet involved in interacting with the chemokine receptor
during HIV entry [19]. Antisera elicited by 363–384 MCP, a
sequence contributing to the CD4 binding pocket, bind to native
gp120 at a lower titer than antisera induced by the other MCPs. The
419–439 MCP elicited antibodies against gp120 in C57Bl/10,
BALB/c, C3H/HeJ, and SWR strains of mice. The 426–441 MCP
elicited antibodies against gp120 in C57Bl/10 and BALB/c, but not
in C3H/HeJ, and the 363–384 MCP only in C3H/HeJ mice.
Although immune responses to the MCPs differ in the three inbred
strains of mice, these 3 MCPs elicited Abs to gp120 in rabbits and in
guinea pigs (not shown).
The Antisera Recognize an Epitope on gp120 Similar to
the MCP Immunogen, and Antisera to the 419–439 or
426–441 MCPs Bind to a Shared Epitope
To ascertain that all Abs in the antisera elicited by MCPs are
binding to epitopes on gp120 similar to the MCP, increasing
concentrations of MCPs were incubated in solution with the Abs
prior to incubating with gp120. In these competition ELISA
experiments, MCPs inhibit the binding of Abs to gp120 in a
concentration-dependent and antigen-specific manner. This
specificity is demonstrated both for several polyclonal antisera
elicited by MCPs (Figure 1A and B) and for MAbs (not shown).
Experiments in which the 419–439 MCP was synthesized in
successively shorter lengths by eliminating amino-terminal resi-
dues, revealed that the dominant epitope recognized by the
antisera and MAbs elicited by the 419–439 MCP was formed by
residues in the carboxy end (data not shown). Therefore we
investigated in parallel the immunogenicity of MCPs of the 419–
439 and 426–441 sequences. The latter sequence adds 2 residues
at the carboxy end and removes 7 residues from the amino end.
The 426 MCP is more immunogenic, eliciting higher titers of
antibodies to gp120, and to both 426 and 419 MCPs (not shown).
As anticipated, antisera elicited by each of these MCPs bound to
both MCPs and the respective MAbs (419 MCP MAb 2D3, and
426 MCP MAb 11A8) cross compete for binding to gp120
(Figure 2).
Antibodies Elicited by MCPs Recognize Specific
Conformationally Dependent Epitopes
In order to assess the extent to which antisera elicited by MCPs
bind to linear contiguous epitopes or conformationally dependent
epitopes, antisera to 3 MCPs were examined for their binding to
‘‘native’’ and to completely denatured recombinant gp120. In the
replicate experiments over a range of dilutions, antisera elicited by
MCPs 419–439 and 426–441 bind to native but not denatured
gp120 (Figure 3, Table 2), indicating that the majority of Abs in
these antisera elicited by the MCPs bind to conformationally
dependent epitopes, and also that these epitopes are accessible to
the Abs. In contrast, antisera to gp120 also contain Abs binding to
denatured gp120 (Figure 3B) in addition to Abs against
conformationally dependent epitopes. Antibodies obtained from
HIV infected individuals also shared these characteristics [58].
Although titers of 363–384 antisera against native gp120 were
clearly lower than titers elicited by the other MCPs (Table 1), the
binding of 363 antisera to completely denatured gp120 also was
decreased by 80 to 100% in multiple experiments, in parallel with
the loss of binding observed with antisera elicited by other MCPs
(Table 2). A 419 MCP MAb (2D3) and 426 MCP MAb (11A8)
also bind to native but not denatured gp120 (Figure 3).
Table 1. MCPs and not the homologous monomeric peptides
elicit antibodies that recognize envelope glycoprotein.
Antisera elicited by Antibody titer to
gp120MN Homologous MCP
Homologous
monomer
419–439 MCP 36,000 850,000 4,800
419–439 monomer 440 610,000 250,000
426–441 MCP 120,000 1,800,000 3,200
426–441 monomer 95 50 ,40
363–384 MCP 680 69,000 44,800
363–384 monomer ,20 ,50 ,50
BALB/c micewereimmunized with 419–439or 426–441MCPsorwithmonomers,
while C3H/HeJ were immunized with 363–384 MCP and monomer. Sera were
collected after the second boost and antibody titers were determined.
doi:10.1371/journal.pone.0008555.t001
Figure 1. Binding of anti MCPs sera to gp120 is blocked by preincubation with the specific MCP immunogen. (A) Antiserum to 426–441
MCP, (B) Antiserum to 363–384 MCP. Sera derived from 426–441 MCP immunized C57Bl/10 mice (diluted 7250 fold) or from 363–384 MCP immunized
C3H/HeJ mice (diluted 140 fold) were incubated with MCPs. Binding of antibodies to gp120 was determined by ELISA.
doi:10.1371/journal.pone.0008555.g001
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binding to reduced carboxy-methylated (RCM) gp120 in which S-
S bonds are disrupted [59] the binding of anti-363–384 sera is
enhanced 100 fold as compared with native gp120 (Table 2). In
contrast, the binding of the other anti-MCP sera to RCM gp120 is
not significantly affected (Table 2). Since the 363 MCP antisera do
not bind to completely denatured gp120, the enhanced binding to
RCM gp120 suggests that the majority of antibodies in the 363
antisera are directed against a residual secondary conformational
epitope on gp120 that is relatively inaccessible in the native
molecule, explaining the lower titer to native gp120. The epitopes
recognized by the 419 MCP and 426 MCP antisera as well as
MAbs (not shown) are accessible on both native gp120 and RCM
gp120 (Figure 3, Table 2). This data also indicates that some
secondary structure remains in RCM gp120, and that some of
these remaining structural epitopes are also accessible on native
gp120. We conclude that the 419–439/426–441 epitopes in native
gp120 are accessible to Abs, but that the majority of epitopes in
native gp120 recognized by Abs elicited by the 363–384 MCP are
not accessible to Abs.
MCPs Elicit Antibodies to Cryptic Epitopes
MCPs can elicit antibodies against cryptic epitopes that are not
immunogenic when presented in the gp120 protein, and against
which Abs may not develop during HIV infection in humans.
Antisera elicited by immunization with rgp120 and antibodies
present in hyper-immune human IgG (HIVIG) bind weakly to
MCPs 419–439, 426–441 or 363–384 (Table 3). Furthermore,
preincubation of gp120 with murine anti-gp120 sera, elicited in
the same strain of mice, up to saturating concentrations does not
block the binding of biotinylated 426 MCP MAb (11A8), whereas
the binding of this MAb is inhibited by antisera elicited by MCPs
derived from this epitope (Figure 4A). Taken together, these two
types of experiments indicate that the administration of an epitope
in the form of a MCP can elicit antibodies accessing cryptic
Figure 2. MAbs 11A8 and 2D3 compete for binding to gp120.
Binding to gp120 of biotinylated 2D3 in the presence of unconjugated
MAbs 2D3 or 11A8 was evaluated in ELISA. Concentration of
biotinylated 2D3 in the assay was 1.2 nM, concentrations of competing,
unconjugated MAbs 2D3 and 11A8 were as indicated.
doi:10.1371/journal.pone.0008555.g002
Table 2. Recognition of native gp120MN and of RCM**
gp120MN by antisera elicited by MCPs.
Antisera to Antibody titer to gp120 Titer ratio
Native Denatured* RCM** (RCM/Native)
363–384 MCP 210 ,50 25,000 119.0
419–439 MCP 100,000 ,50 140,000 1.4
426–441 MCP 300,000 2,500 400,000 1.3
*gp120 was denatured as described in the legend of Figure 2.
**RCM, reduced, carboxymethylated gp120MN.
Sera to 363–384 MCP were harvested after the third boost, and sera to 419–439
MCP or 426–441 MCP after the second boost. Antisera to MCPs 363 and 419
were obtained from C3H/HeJ mice and to 426 MCP from C57Bl/10 mice. ELISA
wells were coated directly with gp120MN native, gp120 denatured (as described
in the legend of Figure 3) or with RCM gp120MN and antibody titers were
determined.
doi:10.1371/journal.pone.0008555.t002
Figure 3. Antibodies elicited by MCPs fail to recognize denatured gp120. Recombinant gp120MN or RCM gp120MN were either maintained
at 4u (control) or were heated for 5 minutes at 95u with 1 mM DTT, 0.1% SDS (denatured). Gp120 was then immobilized in ELISA wells using Ab D7324
and binding of antibodies was determined. Antigens captured on the plate were as follows: (A) gp120 (control); (B) gp120 (denatured). MAbs: 11A8
and 2D3, antisera to MCP 419 and to MCP 426 were all derived from C57Bl/10 immunized mice and antisera to gp120 was derived from C3H/HeJ
mice. All sera and MAb preparations were diluted as indicated in the Figure. Protein concentration of the stock of undiluted MAb preparations used
was, respectively: 1.96 mg/ml (MAb 11A8), and 0.5 mg/ml (MAb 2D3).
doi:10.1371/journal.pone.0008555.g003
Immunogens to Gp120 Epitopes
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8555epitopes on gp120 that are not immunogenic when presented in
the intact glycoprotein. In a parallel type of experiment,
preincubation of gp120 with increasing concentrations (even
beyond data shown) of human HIV Immunoglobulin (HIVIG)
does not inhibit the binding to gp120 of antibodies elicited by 3
different MCPs (Figure 4B) even though the HIVIG binds
strongly, suggesting, but not proving that antibodies against these
epitopes are not present at detectable levels in humans infected
with HIV.
MCPs Elicit a Relatively Focused Range of Antibody
Specificities
Peptide immunogens composed of multiple copies of the same
sequence should elicit a relatively restricted range of Abs focused
on the related epitopes presented by the MCP. Data presented in
this paper emphasize that the majority of Abs present in the whole
antisera elicited by a MCP recognize conserved, cryptic,
conformationally-dependent epitopes, yet experiments on the
functions of these antibodies often employ a MAb in order to
avoid certain nonspecific effects of mouse serum. In order to
estimate the approximate concentration of antibodies in an
antiserum that have the same specificity as a given MAb isolated
from mice immunized with the MCP, we measured the dilution of
antiserum required to compete with the binding to gp120 of a
biotinylated MAb, as compared with the MAb itself. The binding
of the biotinylated MAb is blocked by the homologous
unconjugated 11A8 MAb (Figure 5A). The amount of homologous
unlabeled MAb required to block the binding of biotinylated MAb
by 50% was determined from the linear portion of a standard
curve. Data in Figure 5B in which antisera elicited by MCP 426
are examined for their ability to inhibit the binding of biotinylated
MAb 11A8 to gp120, indicate that a 1:300 dilution of antiserum
gives the same inhibition of binding to gp120 as 0.6 to 1 mg/ml of
the MAb. These data combined with that obtained from
additional 426 MCP sera (not shown) suggest that the antisera
contain antibodies, focused on the same epitope, equivalent to the
MAb 11A8 at concentrations of 240 to 400 mg/ml, although the
relative affinities of the antibodies in the sera are undetermined.
Monoclonal Antibodies (MAbs) Elicited by MCPs Bind to
gp120s from Multiple Clades with Varying Affinities
The MCPs were constructed from a subtype B sequence, and in
repeat experiments MAbs elicited by the MCPs 419 or 426 bind to
clade B gp120 with affinities ranging from 1 to 100 nM, as
estimated by the concentration required to achieve half saturation
of binding. The sequence 419–441 of gp120 is relatively
conserved, but may vary by a few residues within clade B isolates.
Although the overall tertiary structures of gp120s are assumed to
be essentially identical since gp120 of multiple genotypes, and the
envelope protein of SIV, must bind to CD4 and chemokine
receptors, and share domains and many conserved sequences
[19,39,51,60]. These MAbs bind to gp120s from other clades with
lower affinities ranging from 80 to 480 nM undoubtedly reflecting
differences in the primary sequences (Table 4). MAb 11A8 binds
to gp120 of clade B significantly less than MAb b12 (Table 5) but
in the same range.
11A8 MAb Elicited by MCP Binds to HIV Infected Cells
Gp120 exists as a trimer on the viral membrane and on the
surface of infected cells [23,60], and this trimeric structure might
render some epitopes present on monomeric gp120 inaccessible to
Table 3. Antibodies to MCPs are not elicited by immunization
with gp120 or by HIV infection.
Antibody Source Antibody titer to
gp120MN 419–439 426–441 363–384
Murine antisera to gp120MN* 1,970,000 160 200 100
HIV Immunoglobulin** 1,250,000 1,600 1,300 900
ELISA wells were coated with gp120MN or with MCPs listed in the Table, and
antibody titers were determined.
*Sera were obtained from C3H/HeJ mice immunized with gp120MN.
**HIV Immunoglobulin, purified from pooled HIV+ human plasma.
doi:10.1371/journal.pone.0008555.t003
Figure 4. MCPs elicit antibodies to cryptic epitopes of gp120. (A) Binding of MAb 11A8 to gp120 is not inhibited by antisera to gp120.
Competition for gp120MN binding of biotinylated MAb 11A8 and murine sera was evaluated in ELISA as described in Materials and Methods. All
competing sera were obtained from C57Bl/10 mice prior to immunization (preimmune), from mice immunized with 426–441 MCP (130, 000) or with
rgp120MN (550, 000). Titers of sera antibodies recognizing gp120 are listed in parenthesis. Results are expressed as % inhibition of biotinylated 11A8
binding to gp120 by competing antibodies. (B) HIVIG does not inhibit the binding to gp120 of murine antibodies elicited by MCPs 419–439, 363–384
or 105–117. Competition between HIVIG and anti-MCP sera for binding to gp120 was assayed by ELISA as described in Materials and Methods. Gp120
was incubated with HIVIG at the indicated concentrations and the binding of anti-MCP sera (colored lines) from C3H/HeJ mice (anti-MCPs 105–117
and 363–384), C57Bl/10 mice (419–439 MCP) or of HIVIG (shown as black line) was determined. Results are expressed as absorbance at 405 nm.
doi:10.1371/journal.pone.0008555.g004
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anti-426 MCP MAb (11A8) was examined by measuring its
binding to HIV-infected cells using flowcytometry. The MAb
11A8 bound to a larger portion of cells infected with HIV-1 clade
B, with higher mean channel fluorescence, than to uninfected cells
(Figure 6). The specific binding of this antibody was inhibited in a
dose-dependent manner by preincubation with gp120 or with the
homologous but not heterologous MCP (Figure 7). The MAb also
bound to cells infected with HIV from additional clades (Table 5),
and bound with a greater intensity (mean channel fluorescence)
and to more cells infected with an HIV-1 isolate from clade D than
the positive control MAb b12, which is known to bind to
oligomeric gp120 (Figure 8, Table 5). HIVIG bound to cells
infected by HIV from each of these clades to approximately the
same degree except for an isolate from clade E, suggesting that
different gp120s are expressed to approximately the same degree
on these infected cells. The murine isotypic control did not bind to
infected cells. The binding of 11A8 and of b12 to infected cells
does not represent binding of these MAbs to passively bound
gp120 on cells since both MAbs 11A8 and b12 do not detect
soluble rgp120 bound to uninfected CD4 positive cells (Table 6).
In contrast, gp120 passively bound to uninfected cells is detected
by human polyclonal antibodies in HIVIG (Table 6). The failure
of the anti-426 MCP MAb to bind to gp120 complexed with CD4
on uninfected cells also indicates that the epitopes recognized by
this antibody and by MAb b12 are not accessible when gp120 is
bound to CD4.
Interactions between Soluble CD4 and Anti-MCP Abs
The sequences 419–439 and 426–441 are in the b20–b21
hairpin of the bridging sheet [19] and antibodies to these epitopes
might influence the binding of sCD4, or alternatively, sCD4 might
inhibit the binding of the antibodies, either by steric hindrance or
by changing the conformation of the b turn. To examine these
possibilities, gp120 was first incubated with sCD4, which at 10 nM
blocked the binding of anti-MCP sera or MAb 11A8 by 50%. The
same concentration of sCD4 blocked the binding of MAb b12 by
95% (Figure 9A). Reciprocally, MAb 11A8 first incubated with
gp120, inhibited the subsequent binding of sCD4 by 34 to 50%
only at high concentrations of 100 to 600 nM, while MAb b12
inhibited 80% at 1 nM (Figure 9B). As would be expected, a
murine isotypic control MAb does not affect CD4 binding.
Figure 5. Determination of antibodies in 426–441 MCP immune sera that can compete with 11A8 for gp120 binding. Competition of
antibodies and biotinylated 11A8 (0.02 mg/ml) for binding to gp120MN was determined in ELISA as described in Materials and Methods. Source of
competing antibodies: (A) Purified, unconjugated 11A8 - used as a standard; (B) Sera harvested from mice immunized with 426–441 MCP. MAb 11A8
and 426–441 MCP sera were derived from C57Bl/10 mice. Results are expressed as percent inhibition of biotinylated 11A8 binding by competing
antibodies.
doi:10.1371/journal.pone.0008555.g005
Table 4. MAbs elicited by 426–441 MCP (11A8) or 419–439
MCP (2D3) bind to recombinant gp120s derived from HIV-1
clades B, C, E, and A/E.
MAb KD (nM) for gp120
Cl. B Cl. C Cl. E Cl. A/E
MN SF162 BAL SF2 CN54 96ZM651 CM 93TH975 244
11A8 0.56 0.15 100 1.7 220 140 210 240 300
2D3 9 1.4 43 12.5 155 80 480 160 370
*KD the concentration of MAbs resulting in a half saturation of gp120 binding.
Recombinant gp120s derived from different HIV isolates (from clades B, C, E
and A/E, as listed in the Table) were captured in ELISA wells coated with
antibody D7324 and MAb binding was determined by ELISA.
doi:10.1371/journal.pone.0008555.t004
Table 5. MAb 11A8 detects HIV on the surface of cells
infected by HIV isolates from clades A, B, D, and E.
HIV-1 isolate Clade Antibody binding (% positive)
IgG1k* 11A8 IgG1b12 F 105 HIVIG
92UG029 A 0.560.3 13623 3 619 161.4 22610
301596 B 0.660.3 24696 3 682 2 611 39610
UG/93/086 D 0601 9 606 678 611 29612
CMU 08 E 1601 4 63 n.d. n.d. 1569
*Murine IgG1k was used as an isotypic control for MAb 11A8.
CEM-4 cells were infected with HIV isolates from different clades. Cells were
incubated with the antibodies at saturating concentrations and the antibody
binding was determined by flow cytometry using the appropriate secondary
antibodies. Results are expressed as % of cells fluorescing.
doi:10.1371/journal.pone.0008555.t005
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Neutralizing Activity against an Easily Neutralizable HIV
Isolate from Subtype B
To investigate an additional functional property of these MAbs,
we examined the ability of the MAb with the highest affinity for
gp120 (11A8) to neutralize the SF162 isolate, a strain know to be
easily neutralized [56,57]. MAb 11A8, elicited by immunization
with 426–441 MCP, was able to neutralize SF162 by 30 to 65% at
a concentration of 1 mg/ml and 80 to 90% at 30 mg/ml, using a
luciferase construct expressing SF162 gp120 (Figure 10A). The
neutralizing activity was blocked by preincubation of the MAb
with the specific but not an unrelated MCP (Figure 10B). Other
MAbs of lower affinity elicited by 419–439 MCP had little or no
neutralizing activity (not shown).
Discussion
The design of immunogens eliciting broadly neutralizing
antibodies against HIV should be facilitated by approaches that
focus the antibody response on selected, additional epitopes
formed by conserved sequences or included in conserved domains,
and recent studies suggest the existence of a number of additional
neutralizing epitopes [5,16,31,32,33]. Strategies are needed for
identifying additional cryptic, conserved epitopes, to devise
immunogens eliciting Abs against these epitopes, and for
determining whether these epitopes are accessible to antibodies.
These epitopes are more likely to be conserved if they are
conformationally dependent, and must be accessible to antibodies
on oligomeric wild type gp120 [61]. In an attempt to develop such
a strategy, we have explored the immunogenicity of Multiple Copy
Peptides (MCPs) [53,54]. We have reported previously on the
immunogenicity of MCPs encompassing residues 105–117 and
419–439 of gp120, although in most previous experiments binding
to gp160 rather than gp120 usually was measured [53]. We now
describe the specificities and functional properties of the antisera
and MAbs elicited by three different MCPs comprised of peptides
from HIV gp120. In multiple immunizations we have elicited
antisera with these properties to 4 out of 4 selected sequences,
using MCPs representing 4 sequences in 3 different determinants
on gp120 (reference 53 and Results section).
419–439 MCP and 426–441 MCP contain sequences from the
b20–b21 hairpin of the bridging sheet region [19]. This
determinant is in the same structure as that identified as binding
neutralizing Abs recently detected in a broadly neutralizing
human serum [33]. The sequence comprising the 363–384 MCP
contributes a significant portion of the CD4-binding pocket, and
contains conserved residues essential for CD4 binding [19,62,63].
The 363–371 and 425–430 sequences account for 57% of the total
contribution of gp120 to the binding of CD4 [19]. The bridging
region and CD4 binding pocket are logical targets for the
development of neutralizing antibodies, and many naturally
occurring antibodies are directed against the CD4 binding surface
only some of which are neutralizing [12,31,32,33].
The b20–b21 hairpin containing sequences 419–439 and 426–
441 of the bridging sheet might be expected to undergo a
conformational change upon CD4 binding, and preincubation of
gp120 with sCD4 resulted in a modest inhibition of the binding to
gp120 of antibodies to this epitope (Figure 9A). Reciprocally,
preincubation of gp120 with high concentrations of MAb (11A8)
to the 426–441 epitope resulted in a small inhibition of CD4
binding to gp120, far less than achieved by the MAb b12
(Figure 9B).
The binding to gp120 of antisera elicited by MCPs is blocked by
the specific MCP used as the immunogen (Figure 1), indicating
that the antibodies are specific for epitopes on gp120 that cross
react or are conformationally compatible with those of the MCP.
Data presented in additional experiments evaluating the ability of
anti-MCP antibodies to bind to gp120 on infected cells or to
neutralize HIV-1SF162 indicate that these functions also are
inhibited by prior incubation of the antibodies with the MCP
used as the immunogen.
MCPs elicit Abs to cryptic epitopes that are poorly immuno-
genic when native gp120 is used as an immunogen. This is based
on observations that anti-gp120 sera and HIVIG bind poorly to
MCPs 419–439, 426–441 or 363–384 (Table 3). The failure of
antigp120 sera to block the binding to gp120 of a 426 MCP MAb
(Figure 4A) suggests that the 11A8 epitope is cryptic in gp120,
Figure 6. A MAb elicited by 426 MCP (11A8) recognizes HIV-1
on the surface of infected cells. (A) Uninfected CEM-4 cells, (B) CEM-
4 cells infected with HIV-1 clade B. Cells were incubated, as indicated,
with 5 mg of 11A8 or of anti-TNP (isotypic control), or with no primary
antibody (reagent control). Antibody binding was detected using PE-
conjugated secondary antibody and measured by flow cytometry. Flow
histogram plots are displayed.
doi:10.1371/journal.pone.0008555.g006
Figure 7. 11A8 binding to HIV on infected cells is blocked by
gp120 and by homologous MCP. 11A8 was incubated for 30 min at
37u with 426–441 MCP, 363–384 MCP or with gp120 in 2% FCS RPMI
and subsequently the binding of 11A8 to HIV-1 clade B infected CEM-4
cells was assayed. Final concentration of 11A8 in the binding assay was
0.5 mM, and concentrations of competing antigens were as indicated.
MAb 11A8 binding to cells was determined by flow cytometry and %
inhibition of MAb binding by antigens was calculated.
doi:10.1371/journal.pone.0008555.g007
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MAb in antisera to gp120 is not known,
Similarly the failure of HIVIG to block the binding to gp120 of
antisera elicited by MCPs (Figure 4B) suggesting that HIV-infected
humans may not make detectable levels of antibodies against these
epitopes. However the interpretation of this last experiment is
difficult because the mixture of Abs in HIVIG also does not block
the binding of murine anti-gp120 (not shown), suggesting that: a)
at the concentration of the broadly reactive HIVIG employed the
amount of potential competing Abs in HIVIG is too low to block
binding, or b) the majority of epitopes recognized by murine and
human B cells are sufficiently different that similar Abs cannot be
detected in competition assays. It should be noted that the mixture
of antibodies in HIVIG does provide this reagent with potent
neutralizing activity.
These data suggest that the strategy of immunizing with MCPs
may enable one to elicit antibodies to additional cryptic epitopes
on gp120. The data also indicate that cryptic epitopes may be
accessible to Abs elicited by MCPs even though they are not
immunogenic when the intact protein is the immunogen.
Our data suggests that the antibodies in antisera elicited by
MCPs are directed to conformationally dependent epitopes and
not to linear contiguous epitopes (Figure 3A and B, Table 2). The
observation that 363 MCP elicited lower titers of antibodies
Figure 8. 11A8 binds to cells infected by a clade D HIV isolate. CEM-4 cells infected with (A) HIV-1 clade B or (B) with clade D isolate, were
incubated with MAbs 11A8, b12 or with HIVIG at 10 mg/ml. Antibody binding to cells was detected using the appropriate secondary antibodies. The
flow histogram plots of the fluorescence intensity of antibody binding to cells are displayed. (C) Antibody binding to clade D infected cells:
concentration dependence. Clade D infected cells were incubated with MAbs 11A8, MOPC (murine isotypic control), b12, F105 or with HIVIG at the
indicated concentrations. Percentage of cells binding antibody to the cell surface was determined by flow cytometry.
doi:10.1371/journal.pone.0008555.g008
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2) was explained by subsequent experiments demonstrating that
most of the antibodies induced by 363 MCP were directed against
epitopes accessible in RCM gp120 in which S-S bonds are
disrupted (Table 2).
By contrast, binding of antisera or MAbs elicited by MCPs 419
or 426 to RCM gp120 and native gp120 was similar, indicating
that binding sites for the 418 or 426 epitopes are present in an
accessible form in both native and RCM gp120. However, all of
these antibodies failed to bind to fully denatured gp120, suggesting
that residual secondary structures able to bind these antibodies are
present in RCM gp120. It has been demonstrated previously that
interactions between b sheets can drive partial folding of gp120
even after a critical S-S bond has been eliminated [64,65]. This
result suggests that the majority of antibodies elicited by the 363
MCP are directed against secondary structures that are inacces-
sible in the native gp120, but that some of the antibodies bind to
more accessible epitopes in the CD4 binding region of native
gp120, since the binding of these Abs is blocked by the 363 MCP
immunogen and is lost when gp120 is completely denatured. The
ability of 363 MCP to elicit some antibodies binding to more
accessible epitopes in the CD4 binding region of native gp120 is of
interest in light of the recent finding that some neutralizing
antibodies in the sera of patients with broadly neutralizing activity
are directed against epitopes in this region [32,33], and that a
broadly neutralizing Ab like b12 may initially bind to the epitopes
around the binding pocket at low affinity and then bind the
interior of the CD4 binding pocket [66].
Epitopes binding antibodies elicited by the 426 MCP also are
accessible on oligomeric gp120 as indicated by the ability of the
antibodies to bind to gp120 of budding virus on the surface of
infected cells (Figures 6–8 and Table 5). Binding of an Ab to
infected cells is frequently used as a surrogate for binding to gp120
in its trimeric form, although monomers and dimers may also be
present on the surface of HIV-infected cells [61]. MAb b12 is
known to bind to gp120 in its trimeric form, and MAb elicited by
the 426 MCP also bound to cells infected with several subtypes of
HIV in approximately the same range as b12, and bound at
greater intensity to more cells infected with clade D virus (Figure 8).
Control experiments demonstrate that the binding of 11A8 to
infected cells is specifically blocked by preincubation of antibody
with homologous MCP (Figure 7) and that 11A8 does not detect
gp120 passively bound to CD4 on cells (Table 6). Similarly, the
neutralizing activity of a MAb elicited by 426 MCP against
the easily neutralized SF162 is inhibited by preincubation of the
antibody with the immunogen (Figure 10).
The MCPs used as immunogens were constructed using
sequences from Clade B isolates, and while the elicited antisera
bind most avidly to gp120 of clade B viruses, they also bind at a
lower affinity to rgp120 from other clades (Table 4). A MAb
elicited by 426 MCP demonstrates a similar breadth of binding to
oligomeric gp120 on cells infected with viruses from different
clades, and actually detects virus at a higher intensity and on more
cells infected with a clade D isolate than does the MAb b12
(Table 5 and Figure 8).
Our hypothesis is that in MCPs the peptides, consisting of 15 to
21 residues, when coupled at the carboxyl end to the lysine core
and constrained by 7 adjacent chains, assume a conformation
compatible with that in the intact gp120. These secondary
structural epitopes are immunogenic when presented in MCPs
and also are present and often accessible in native gp120, whereas
Table 6. MAb 11A8 does not recognize gp120 passively
bound to uninfected CEM-4 cells.
Antibody Ab binding (% positive)
gp120MN Control
None* 0.1 0.1
11A8* 1.2 0.9
None** 1.5 1.3
IgG1b12** 1.3 1.4
HIVIG** 96.2 1.3
CEM-4 cells were incubated for 2 h at 4uC with gp120MN (0.24 mg/ml) or with no
gp120 (control), washed, then incubated with the primary antibodies (10 mg/
ml) listed in the Table. Antibody binding to cells was determined by flow
cytometry. Results are expressed as % of cells fluorescing. Secondary
antibodies:
*anti-mouse.
**anti-human.
doi:10.1371/journal.pone.0008555.t006
Figure 9. Antibodies elicited by MCPs 419 and 426 partially compete for CD4 binding to gp120. (A) CD4 inhibition of antibodies binding
to gp120. (B) MAb 11A8 weakly inhibits CD4 binding to gp120. Reciprocal competition of CD4 and antibodies for binding to gp120 was evaluated by
ELISA as described in Materials and Methods with gp120 captured on the antibody to the C-terminal sequence of gp120.
doi:10.1371/journal.pone.0008555.g009
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elicited by MCPs recognize native gp120 but not denatured
gp120, and modulate functions of the native protein. The strong
recognition of conformational epitopes and poor recognition of
contiguous linear epitopes (as in native but not denatured gp120) is
a property of the whole antisera as well as MAbs, and does not
represent a selection of one MAb that was elicited by
immunization with the MCP. While we do not know the total
amount of Ab against gp120 elicited by immunization with the
MCPs, the competition ELISA studies (Figure 5) indicate that the
antisera contain substantial amounts of Abs equivalent to 11A8,
focused on the same epitope.
The difficulty in eliciting broadly neutralizing Abs to gp120 has
been attributed to either the lack of immunogenicity of conserved
epitopes, or the inaccessibility of these epitopes to antibodies if
they are formed (as reviewed in [61]. The experiments described
provide examples of each of these explanations. Both the MCPs
419 and 426 and the 363 MCP elicit antibodies to epitopes that
are not immunogenic when presented to the immune system as
native glycoprotein, and while epitopes in native gp120 are
accessible to the Abs elicited by MCPs 419 and 426, most (but not
all) of the antibodies elicited by the 363 MCP are directed against
epitopes not accessible in the native glycoprotein.
Many additional conserved cryptic epitopes may be immuno-
genic if presented in the form of MCPs, and some of them may
also be accessible on native gp120. Once Abs are elicited by a new
MCP, these Abs can be used as reagents to determine whether the
new epitope is accessible on monomeric and trimeric gp120.
Other conserved structures may not be immunogenic because they
are recognized by the immune system as being self.
The 3 MCPs reported in this paper do not elicit broadly
neutralizing antibodies, even though modest neutralizing activity
has been observed, and broadly reactive binding to cells infected
with different subtypes has been demonstrated. Although the
amino acid sequence encompassing residues 426–441 differs by 3
residues between 426 MCP and the SF162, the MAb elicited by
this MCP neutralized SF162. However, these experiments do
provide a strategy for eliciting antibodies to other conserved and
accessible epitopes on 120 that are not immunogenic when
presented in the whole glycoprotein. Although regions of gp120
associated with critical conformational changes or with binding to
cells should be targets for neutralizing antibodies, additional
conserved, accessible epitopes in non-functional regions also
should be identified and studied. A combination of several MCPs
representing epitopes broadly conserved across genotypes of HIV-
1 might be effective in a prime-boost immunization schedule to
focus the immune response on conserved and otherwise cryptic
epitopes. Recent, increasingly precise identification of epitopes
recognized by broadly neutralizing MAbs identified by repertoire
screening or by broadly neutralizing antibodies in the sera of many
infected individuals [5,16,32,33] should provide opportunities to
evaluate the strategy of immunizing with specific MCPs
resembling these epitopes.
Materials and Methods
HIV-1 gp120 Derived Peptides
Peptides derived from conserved domains of gp120 were
synthesized as monomers, or high molecular weight Multiple
Copy Peptides (MCP). Amino acid sequences of the peptides and
their numerical location in gp120 (in parenthesis) as in the Los
Alamos National Laboratory HIV Sequences Compendium were
as follows: 1) RIKQIINMWQEVGKAMYAPPI (amino acids
419–439),
2) MWQEVGKAMYAPPIEG (amino acids 426–441),
3) QSSGGDPEIVTHSFNCGGEFFY (amino acids 363–384),
4) HEDIISLWDQSLK (amino acids 105–117). These amino
acid sequences are identical to sequences in HIV-1 HXB2. The
MCPs, containing 8 identical peptides covalently attached to a
polylysine core through the triglycine spacers were synthesized as
described previously [53,54]. Briefly, 8 copies of identical amino
acid sequence were manually synthesized on the core using solid
phase peptide synthesis F-moc chemistry. The major peak was
then HPLC purified using a C18 reverse phase column and
peptide sequence verified by amino acid analysis. Peptides were
repeatedly synthesized at Anaspec (San Jose, CA) and the 363–384
MCP was also synthesized at Louisiana State University Health
Sciences Center Core Laboratory (New Orleans, LA). 363–384
MCPs obtained from both sources elicited similar immune
responses. The MCPs are referred to in the text as: 1) 419–439
Figure 10. MAb 11A8 neutralizes SF162 pseudovirus. (A) Concentration curve of 11A8 and the murine isotypic control anti-TNP for SF162
pseudovirus neutralization. (B) Neutralization of SF162 by 11A8 is abolished by preincubation with the homologous MCP. MAb 11A8 was incubated
before neutralization assay for 1 h at 37u with 426–441 MCP or 105–117 MCP or with medium (control). The final concentration of 11A8 in
neutralization assay was 0.1 mM and of the MCPs was 1 mM.
doi:10.1371/journal.pone.0008555.g010
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MCP or 363 MCP and 4) 105–117 MCP or 105 MCP.
Recombinant HIV-1 Envelope Glycoproteins
gp120CM, gp120CN54, gp12093TH975, gp120BAL, gp12096ZM651,
gp120SF162 were obtained from the NIH AIDS Research and
Reference Reagent Program. Gp120SF2 was also obtained as a gift
from Chiron Corporation. Gp120MN and the reduced and
carboxymethylated (RCM) gp120MN [59] were gifts from Vaxgene
and Gp120LAV-1 was a gift from Protein Sciences, Inc.
HIV-1 Isolates
HIV-1 syncytia inducing isolates: 92UG029, Clade A; 301596,
Clade B; UG/93/086, Clade D; 92TH251, Clade E; donated by
the WHO Network for HIV Isolation and Characterization were
obtained from the NIH AIDS Research and Reference Reagent
Program. These isolates were subsequently adapted to growth in
CEM-4 cells. The cell free viral culture supernatants were stored
as aliquots at 2138u. Infectivity titers of these HIV-1 culture viral
stocks were determined in CEM-4 cells using software (ID50
program version 5) developed by Dr. J. Spouge.
Other Materials
Human lymphoblastoid cell line, CEM-T4, human HIV
immune globulin (HIVIG), human MAbs IgG1b12 [67] and
F105 [12] as well as rabbit anti-sera to human CD4 were obtained
from the NIH AIDS Research and Reference Reagent Program.
Recombinant soluble human CD4 was purchased from Progenics
Pharmaceuticals, Inc. (Tarrytown, NY). Murine isotypic controls:
IgG1k: anti-TNP-keyhole limpet hemocyanin and MOPC 31-C
were purchased from BD Biosciences–Pharmingen (San Diego,
CA) and from Sigma, respectively. (Fab)2 fragments of affinity
purified conjugated antibodies: peroxidase-goat anti-murine IgG;
peroxidase-goat anti-human IgG (H+L), R-Phycoerythrine (PE)-
goat-anti-mouse IgG (H+L), Fluorescein (FITC)-goat anti-human
IgG (H+L) and peroxidase conjugated goat anti-rabbit IgG were
purchased from Jackson ImmunoResearch Laboratories, Inc.
(West Grove, PA). PE-conjugated murine MAb to human CD4
was purchased from BD Biosciences (San Jose, CA).
Immunization of Animals
C3H/HeJ, SWR, or C57BL/10 inbred mice were obtained
from Jackson Laboratories, and BALB/c mice were obtained from
Taconic. The animals were maintained according to the protocol
approved by the Institutional Animal Care and Use Committee of
New York University School of Medicine. Mice were immunized
(4 mice per experimental group) as described previously [53] with
antigens emulsified in CFA (50 mg of peptides or 10 mgo f
gp120MN) and boosted twice at three week intervals with antigens
emulsified in IFA (25 mg of peptides or 10 mg of gp120 MN). Sera
were collected prior to immunization, 2 weeks after boosts and Ab
titers were determined on sera from individual mice and on pooled
sera from each experimental group.
Binding Assays
Determination of Abs binding to antigens and determination of
Ab titers was performed by enzyme linked immunoadsorbent
assay (ELISA) as previously described [53]. Briefly, ELISA plates
were coated with most antigens at 1 mg/ml, blocked with casein in
PBS, incubated with antibodies, and bound Abs were detected
with the appropriate peroxidase-conjugated second antibodies.
Plates were washed, substrate was added [1 mM 2,29-azino-bis 3-
ethylbenzthiazoline-6-sulfonic acid (Sigma) and 0.01% hydrogen
peroxide] and after 1 h incubation the absorbance was determined
at 405 nm. Antisera dilution at which an absorbance reading of
0.5 was obtained was determined by linear interpolation and the
reciprocal of this dilution was taken as a titer. Binding of Abs to
gp120 was assayed by capture ELISA in which gp120 was
immobilized in ELISA wells using sheep antibody D7324 (Cliniqa,
Inc., Fallbrook, CA) to a conserved amino acid sequence from C-
terminal of gp120, that can react with both native and denatured
recombinant gp120 in ELISA [58]. This assay was carried out as
described elsewhere [20] with the following modifications: ELISA
wells were coated with D7234 antibody dissolved in PBS, wells
were blocked with 2% casein in PBS and gp120 was added to the
wells in 0.2% casein, PBS. Antibodies bound to gp120 were
detected as described in measurement of antibody titers.
Competition for Antibody Binding to gp120
Ability of MCPs to inhibit binding of Abs to gp120 was tested as
previously described [53]. Briefly, sera samples were incubated for
1 h at 37u with MCPs at the indicated concentrations (or without
MCP–control) and Ab binding to gp120MN was subsequently
tested by ELISA. The appropriate dilution of sera was chosen to
give an absorbance reading between 1 and 2 as determined from
previous titration of Abs binding to gp120MN. Reduction of Ab
binding was determined by comparison of binding in the presence
or absence of MCP and is expressed as percent binding inhibition.
Competition between Abs for binding to gp120 was determined by
ELISA with gp120MN captured on the plate wells. The competing
Abs were added to the wells in 100 ml and plates were incubated
for 1 h at 37u. Plates were subsequently washed three times to
eliminate nonspecific background effects observed with preim-
mune sera. The biotinylated test antibody MAb 11A8 was added
and its binding was determined with peroxidase conjugated
streptavidin. The appropriate dilution of the test Ab was
determined from a previous Ab titration of its binding to gp120
and was chosen to give absorbance reading between 1 and 2. The
experimental samples were done in duplicate and the test antibody
control (without the competing Abs) was done in quadruplicates.
Reduction of absorbance readings in the presence of competing
Abs was determined and the values for each sample were
expressed as percent inhibition of Ab binding to gp120.
Determination of Reciprocal Inhibition of Antibodies and
CD4 for Binding to gp120
CD4 inhibition of Ab binding: CD4 at the appropriate
concentrations was added to the ELISA wells coated with
gp120MN captured with Ab D7324. After 1 h incubation at room
temperature antibodies were added (diluted to give an absorbance
reading between 1 and 2). Subsequently plates were incubated for
1 h at 37u and Ab binding to gp120 was determined. The
reduction of absorbance reading in the presence and absence of
CD4 was determined and was expressed as percent inhibition of
Ab binding.
Ab inhibition of CD4 binding: Abs at the appropriate
concentrations were incubated for 30 minutes at 37u with
gp120MN captured with Ab D7324 in ELISA wells. Subsequently
CD4 was added and plates were incubated for 1 hour at 37u.
Both MAb 11A8 and CD4 were added in 50 ml aliquots. Bound
CD4 was detected using rabbit anti-sera to human CD4 and
peroxidase conjugated goat anti-rabbit IgG. CD4 concentration
used determined from previous titration of CD4 binding to gp120
and was calculated to give the final absorbance value of 1–2. The
reduction of absorbance reading in presence or absence of Abs
was determined and expressed as percent inhibition of CD4
binding.
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Characterization of Monoclonal Antibodies
C57BL/10 mice were immunized with 419–439 MCP or with
the 426–441 MCP as described above. Cells from spleens of
immunized mice were fused with SP2/0 meyoloma cells as
described previously [68]. Hybridomas were cultured in RPMI
1640 supplemented with 20% fetal bovine serum,1% glutamine,
1% penicillin, streptomycin and 55 mM mercaptoethanol. All
media components (obtained from Sigma) were hybridoma grade
with the exception of mercaptoethanol (GIBCOBRL). Hybridoma
supernatants were screened by ELISA using peptide immunogens
or gp120MN. Selected hybridomas were subcloned at least 3 times.
MAb 11A8 (referred to as 426 MAb) was obtained from 426–441
MCP immunized mice, while MAbs 2D3 (referred to as 419 MAb)
and 4C2 were obtained from 419–439 MCP immunized mice.
Monoclonal antibodies were produced in CeLLine Bioreactor
flasks (Wilson Wolf Manufacturing, New Brighton, MN) by
hybridomas cultured at high density in serum free medium
(Sigma), purified by affinity chromatography on Sepharose
coupled to protein G (Pharmacia) and dialyzed against PBS.
Protein concentration in the MAb preparations was quantified
using Coumassie Plus Protein Reagent, murine IgG concentration
was determined using an Antibody Assay kit (both obtained from
Pierce Biotechnology, Rockford, IL). Concentrations of protein
and of IgG in these MAb preparations were determined to be
comparable. Isotype of MAbs 11A8, 2D3 was determined to be
IgG1k using an Isostrip from Roche Diagnostic Co. (Indianapolis,
IND). MAbs were biotinylated with N-hydroxysuccinimide biotin
ester (diluted in DMSO) in 0.1 M NAHCO3 (according to the
protocol provided by Pierce Biotechnology). Biotinylated MAbs
were dialyzed against PBS. The relative affinity of MAbs for
rgp120, expressed as a concentration of MAb at which 50%
maximal binding to gp120 was observed, was determined in
ELISA with gp120 captured by D7324 antibody.
Binding of MAbs to HIV Infected Cells
CEM-4 cells were infected with CEM-4 adapted HIV-1 in the
presence of polybrene (as described above). The course of infection
was followed by measurement of cell viability by trypan blue
staining and loss of surface expression of CD4 (determined using
PE-conjugated MAb to human CD4). To reduce nonspecific
antibody binding to CEM-4 cells, cells were incubated in RPMI
with 10% human serum for 1 h at 37u and washed at 4u with PBS
supplemented with 2% FBS, 0.05% azide (FA buffer). Cells
(2610
5 in 100 ml FA buffer) were incubated with Abs at the
indicated concentrations. The bound Abs were detected using (as
required): PE-conjugated (Fab9)2 fragments of goat anti-mouse
IgG (H+L) or Fluorescein (FITC)-conjugated (Fab9)2 fragments of
goat anti-human IgG (H+L). Both incubations were carried out at
4u for 30 minutes. Cells were washed after each incubation with
FA buffer, fixed with 1% formaldehyde in PBS and analyzed by
flow cytometry using FACScan (Becton Dickenson). Gates were set
on the live cell population and fluorescence negative peak was
defined on unstained cells.
Neutralization Assay
Neutralization of SF162 pseudovirions in a single-cycle
infectivity assay was measured as described [56] except that
TZM-bl cells were used for virion culture. Briefly, pseudovirion
suspensions were incubated for 1.5 h at 37u with Abs. These
mixtures were added to the wells of 96 well plates in which TZM-
bl cells were seeded in growth medium containing 1 mg/ml
polybrene. After 3 day incubation cells were lysed and luciferase
activity was determined in each well with Luciferase Substrate
(Promega) using Lumimark Plus microplate reader. The reduction
of activity was determined by comparison of the relative units of
luminescence in the presence and absence of MAbs and is
expressed as percent neutralization. A human anti-V3 MAb 447-
52D known to have neutralizing activity [8] and a murine isotypic
control anti-TNP were also included in the assays as controls.
Data presented for all experiments are representative examples
of at least three replicate experiments.
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